Compare Kimco Realty Corporation (HC) Common Stock (KIM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimco Realty Corporation (HC) Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Kimco Realty Corporation (HC) Common Stock trades at $22.48 (market cap $15.06B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Kimco Realty Corporation (HC) Common Stock is far larger — about 2× Spyre Therapeutics Inc. Common Stock's market cap, and Kimco Realty Corporation (HC) Common Stock pays a 4.99% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimco Realty Corporation (HC) Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KIM | SYRE | |
|---|---|---|
Market Cap | $15.06B | $7.52B |
Volume | 6,246,987 | 1,441,031 |
Sector | Real Estate | Health |
52-Week High | $26.38 | $108.92 |
52-Week Low | $19.78 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $23.22B | $6.52B |
Dividend Yield | 4.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KIM trades at $22.45, up 0.58% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Fundamentals show robust profitability with a 27.76% net income margin and a P/E of 26.1. Analyst consensus is a Buy with a $26.09 price target, though technical indicators suggest near-term caution.
The outlook for KIM is mixed; strong fundamentals and positive analyst sentiment support upside, but technical bearishness and macroeconomic risks pose challenges. Investment opportunity lies in its high dividend yield and earnings growth, while risks include market volatility and real estate sector headwinds. The stock's performance will hinge on upcoming earnings and broader economic conditions.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kimco Realty Corporation (HC) Common Stock
Kimco Realty is a real estate investment trust that owns and operates open-air, grocery-anchored shopping centers and mixed-use properties in the United States.
Read more on KIM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
